TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00002580
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002580
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002580
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02711202
Drug: MabCampath,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day 2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.
Study: NCT02356679
Drug: Eupasidin-s Tab
Normalized name: S-adenosylmethionine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: three times per day, 1 tab for each time, PO, during 2weeks
Study: NCT02356679
Drug: Stillen Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: three times per day, 1 tab for each time, PO, during 2weeks
Study: NCT03180307
Drug: OTL38
Normalized name: Fluorodeoxyglucose F 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025 mg/kg of OTL38 in 250ml dextrose 5% in water (D5W) infused intravenously over 60 minutes
Study: NCT02910102
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily, oral
Study: NCT03401060
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subcutaneous injection will occur every 6 months during 3 years for a total of 7 injections
Study: NCT02540265
Drug: Intravenous Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01590654
Drug: Single Ascending Dose (SAD) Cohorts GS-9620
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
Study: NCT00472966
Drug: Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply cream once daily at night. Subjects will be asked to discontinue use of Fluocinolone acetonide/hydroquinone/tretinoin Cream 2 days prior to the peel and restart 2 days after the peel; Glycolic Acid Peels - In office treatment at weeks 2, 4, 6, 8 and 10
Study: NCT01636128
Drug: difluoromethylornithine
Normalized name: α-difluoromethylornithine
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg oral for 14 days, combined with sulindac for 15 days
Study: NCT01636128
Drug: Sulindac
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg oral for 15 days, combined with DFMO for 14 days
Study: NCT02399137
Drug: MM-141
Normalized name: inositol 141 MG
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02399137
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00955513
Drug: diclofenac diethylamine gel 2.32%
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac diethylamine gel 2.32% twice a day
Study: NCT00955513
Drug: diclofenac diethylamine gel 2.32%
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac diethylamine gel 2.32% three times a day
Study: NCT00955513
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00666965
Drug: SPM 962
Approvals — FDA: no, EMA: no, PMDA: no
Description: transdermal application, 1 time per day, 0-6.75 mg/body, titration, 6weeks
Study: NCT02861482
Drug: Blood Product
Normalized name: Blood product
Approvals — FDA: no, EMA: no, PMDA: no
Description: transfusion of blood product if necessary no matter which surgical procedure has been taken
Study: NCT04629846
Drug: QL1209
Approvals — FDA: no, EMA: no, PMDA: no
Description: QL1209 IV infusion in 3-week cycles. Prior to surgery (neoadjuvant treatment): 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4.
Study: NCT01323140
Drug: testosterone matrix transdermal system
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01371305
Drug: BG00011
Approvals — FDA: no, EMA: no, PMDA: no
Description: BG00011 will be administered at varying doses via subcutaneous (SC) injection
Study: NCT01371305
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile normal saline (0.9% Sodium Chloride for Injection) via Subcutaneous (SC) injections.
Study: NCT00049660
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00586976
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion at 4 ml/hour for 64 hours.
Study: NCT00504894
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A low dose given intravenously one time for just under an hour while the subject is shown visually stimulating images in an MRI machine.
Study: NCT04394936
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodiumchloride 0,9% solution for injection
Study: NCT00001967
Drug: HAART
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02605174
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two placebo tablets to match lasmiditan doses.
Study: NCT01140061
Drug: Placebo Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patches matching MK-0873 0.05%, 0.5%, or 2% patches
Study: NCT01140061
Drug: Placebo Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream matching MK-0873 0.05%, 0.5%, or 2%
Study: NCT01140061
Drug: Plain patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain patch containing no MK-0873 or placebo
Study: NCT01078844
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Look-alike placebo
Study: NCT00002921
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04379076
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) placebo (normal saline) at the same frequency
Study: NCT01587235
Drug: Ezetimibe/simvastatin
Normalized name: EZETIMIBE/SIMVASTATIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithm based treatment using 10/10mg, 10/20mg and 10/40mg ezetimibe/simvastatin combination tablets orally once daily.
Study: NCT01587235
Drug: Other Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants are prescribed a statin (any other than Vytorin) as per routine standard of care
Study: NCT02217917
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched Placebo administered as single dose subcutaneously with rHuPH20.
Study: NCT02217917
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched Placebo administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20.
Study: NCT02126839
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo delivered via a multidose dry powder inhaler (MDPI).
Study: NCT02126839
Drug: ProAir HFA inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue medication, ProAir hydrofluoroalkane (HFA) inhaler, was dispensed at the run-in visit for the relief of asthma symptoms to be administered as needed.
Study: NCT01735370
Drug: Etodolac Tablets USP 500mg
Normalized name: etodolac Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg tablet once a day
Study: NCT01735370
Drug: Etodolac Tablets USP 500 mg
Normalized name: etodolac Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg tablet once a day
Study: NCT00332891
Drug: SR58611A
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02146625
Drug: CJ-40002
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02055300
Drug: LY03005
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02055300
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02113358
Drug: Intravenous colloid bolus with Voluven
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00934674
Drug: SKI-606 (Bosutinib)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm 1 - Commercial Tablet manufactured by Excella~Arm 2 - Clinical Tablet manufactured by Wyeth Montreal
Study: NCT01706783
Drug: Norditropin NordiFlex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (s.c., under the skin) administration daily for 28 days. The daily dosing will be the same as the pre-trial daily dose of human growth hormone (hGH) taken by the adult with growth hormone deficiency
Study: NCT03489928
Drug: Dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 - 1-2mg gel manufactured for vaginal use; placed vaginally every 6 hours as needed.
Study: NCT01106235
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00493818
Drug: GSK690693
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00474617
Drug: Rocurium
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous (IV) single bolus dose of 0.6 mg.kg-1
Study: NCT02349685
Drug: 14 day PBMT group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue therapy using 14 day PBMT regimen \[Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d\]
Study: NCT01755455
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsule
Study: NCT01106508
Drug: LEQ506
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03350906
Drug: n3-PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: The DHA/EPA softgels will each contain \~465mg of EPA and \~375mg of DHA for a total daily dosage of 3.4g/day. Additionally, each capsule will contain SCI's proprietary Advance Lipid TechnologiesTM (ALTTM) containing the surfactants polysorbate 80, NF (\~381 mg) and poloxamer 237, NF (\~8.8 mg).
Study: NCT03350906
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Looks exactly like the study drug but contains soybean oil with no active ingredient.
Study: NCT01701934
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo pill daily, for 6 months
Study: NCT00331188
Drug: Sanvar® (vapreotide)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00017290
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03502902
Drug: HEC 68498
Normalized name: ALCOHOL 73 L in 100 L TOPICAL GEL [Grand Valley Reagents HEC Hand Sanitizer Gel]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEC68498 is a potent,highly selective inhibitor of class 1 isozymes of phosphoinositide 3-kinase/mammalian(PI3K) and of the mammalian target of rapamycin (mTOR). It has shown good activity against fibrosis and inflammation in vitro and in vivo, with a lower effective dose and better efficacy than pirfenidone and nintedanib.
Study: NCT03502902
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03150628
Drug: HIPEC
Normalized name: Hyperthermic Intraperitoneal Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperthermic intraperitoneal chemotherapy (HIPEC) with 100mg/m2 cisplatin
Study: NCT04029571
Drug: TCM-FMD
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Apply fastening-mimicking diet combined with a dispelling dampness meal replacement. For the convenience of implementation, a cycle of 4 weeks. The first 5 days of each cycle is the calorie restriction stage (daily calorie about 800kcal). The traditional Chinese medicine with dampness effect is used as the main source of calories in this stage. The normal diet is carried out under the guidance of a professional dietitian for the next 23 days. Study for 12 weeks.
Study: NCT00248716
Drug: Ferrous gluconate and iron polysaccharide complex
Normalized name: ferrous fumarate / polysaccharide iron complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children with anemia will receive 5mg per kg per day of one of study medications. Treatment period for 3 months
Study: NCT03204253
Drug: rFSH + r-LH in combination
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: 29 women stimulated with rFSH supplemented by rLH in the late follicular phase started at the same time of starting the antagonist administration.
Study: NCT02087722
Drug: KI1001
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02087722
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01656070
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01437826
Drug: antioxidants
Normalized name: E Complex with Antioxidants
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets composed of 200 mcg selenium \[as l-selenomethionine\], 30 mg zinc, 2 mg vitamin A \[retinol\], 180 mg vitamin C \[ascorbic acid\] and 30 mg vitamin E \[D-α-tocopherol acetate\]
Study: NCT01437826
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo had an identical appearance as intervention
Study: NCT01493882
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form = tablet, route = oral administration, once daily from Week 0 to Week 24 for Part 1 and Part 2
Study: NCT01278082
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating daily dosing with 2 placebo capsules OD and 1 placebo capsule OD every second day.
Study: NCT01641822
Drug: Placebo to match AZLI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match AZLI 3 times daily combined with diluent administered using an eFlow nebulizer
Study: NCT03403309
Drug: 1) Inosine 5'-monophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1) Subjects are initiated with 1 tablet (500mg of inosine 5'-monophosphate per one tablet) two times per day, and then titrated up by 1 tablet per every visit up to visit 2, i.e. increased up to 2 tablets two times a day by week 6. A maximum limit of elevated serum uric acid level is 9 mg/dL, so that reducing dose of administration may be considered in case of being way over the top of limited level.
Study: NCT03403309
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2) Subjects are initiated with 1 tablet (500mg of placebo tablet with inactive therapeutic effect) two times a day, and then titrated up by 1 tablet per every visit up to visit 2, i.e. increased up to 2 tablets two times a day by week 6. A maximum limit of elevated serum uric acid level is 9 mg/dL.
Study: NCT02251210
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04122170
Drug: Aspirin (ASA) Oral Tablet - Pre-Treatment
Normalized name: aspirin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 81 mg oral tablet; administered daily between Day -7 to the morning before receiving study medication on Day 1, for a total of 8 tablets only.
Study: NCT04122170
Drug: Placebo (0.9% Sodium chloride) infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Sodium chloride Intravenous Infusion over a 16 hour duration
Study: NCT01665352
Drug: TTP054
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally once daily for 12 weeks.
Study: NCT01665352
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally once daily for 12 weeks.
Study: NCT01033318
Drug: MK1809
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral doses of MK1809
Study: NCT01033318
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to MK1809
Study: NCT05338723
Drug: Rosuvastatin 20mg
Normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg of oral rosuvastatin 24 hours prior to the first cycle of chemotherapy and once daily for the rest of the follow-up period (6 months).
Study: NCT01532115
Drug: BIA 9-1067
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg and 800 mg of BIA 9-1067 (single-dose)
Study: NCT01532115
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single-dose
Study: NCT01771445
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg, s.c., once only
Study: NCT01675362
Drug: Antioxidant group
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: They will be receive vitamins A, C, E and selenium (Selenium ACE) Dosage: Two tablets before ESWL Then 2 tablets every 8 hours after ESWL for one week
Study: NCT01675362
Drug: Calcium Channel Blockers
Normalized name: CALCIUM CHANNEL BLOCKERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: They will receive Verapamil (Isoptin 80 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every 12 hours after ESWL for one week
Study: NCT01675362
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: They will receive placebo
Study: NCT01049113
Drug: ON 013105
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-hour intravenous infusion once a week. Starting dose is 17 mg. Maximum dose will be 1525 mg.
Study: NCT03233438
Drug: Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
Study: NCT02001857
Drug: 1 TachoSil hemostatic sponge (9,5 cm x 4,8 cm) placed on each side on the external iliac artery.
Approvals — FDA: no, EMA: no, PMDA: no
Description: at the end of surgery
Study: NCT01928368
Drug: AMG 282 Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of matching AMG 282 placebo either subcutaneously or intravenously on day 1.
Study: NCT00854633
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, twice per day
Study: NCT01205477
Drug: EXPERIMENTAL
Normalized name: WA-001 Experimental Soil Surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infiltration of 40 mg of methylprednisolone acetate plus 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days
Study: NCT01205477
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infiltration of 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days
Study: NCT03437824
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Sodium Chloride, Once
Study: NCT03249103
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules.
Study: NCT03688100
Drug: Medication Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative care model will be used. The medication management group will meet with the patient in a one 50 minute in person introductory antidepressant medication treatment session to educate the patient about depression and medication options. Patients will get prescribed a standard of care anti-depressant medication by treating physician, followed by 12 weekly follow up telephone visits, then on a monthly basis for 3 months, and then as needed thereafter.
Study: NCT00494507
Drug: Placebo (double-blind)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive substance manufactured to look like Dichlorphenamide 50mg tablet
Study: NCT01577472
Drug: High Dose Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is added to a high dose of HMG (450 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
Study: NCT01577472
Drug: Low dose Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is added to a low dose of HMG (150 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
Study: NCT04005079
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of Care
Study: NCT00683969
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: po bid for 36 weeks
Study: NCT00295932
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01416480
Drug: Theobromine 300mg
DrugBank: Theobromine (DB01412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, b.i.d.
Study: NCT03779074
Drug: 10d bismuth quadruple therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabeprazole 20 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, tetracycline 500 mg and metronidazole 250 mg q.i.d. for 10 days
Study: NCT03779074
Drug: 14d hybrid therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a dual regimen with rabeprazole 20 mg and amoxicillin 1 g b.i.d. for 7 days followed by a quadruple regimen with rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg b.i.d. for 7 days
Study: NCT03779074
Drug: 14D high-dose dual therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabeprazole 20 mg and amoxicillin 750 mg q.i.d. for 14 days
Study: NCT03235167
Drug: CpG DNA
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: CpG DNA concentrate
Study: NCT03235167
Drug: Placebo - Concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: CpG DNA vehicle
Study: NCT04305743
Drug: OnabotulinumtoxinA 100 UNT
Normalized name: onabotulinumtoxinA 100 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradetrusor onabotulinumtoxin A is administered cystoscopically with 100 unit dose given as either 5 or 20 injections in a single procedure based on the arm the participant is randomized into.
Study: NCT03178669
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution manufactured to mimic cobitolimod
Study: NCT02540993
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo, oral tablet, once daily in the morning, until the trial was completed provided there were no safety grounds for discontinuing treatment
Study: NCT00332553
Drug: 17 beta estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01438177
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00079677
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets once daily
Study: NCT04462939
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active ingredients except of 225 μg iodine; One capsule daily, oral
Study: NCT02982083
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 patients consume placebo oral tablets daily for one year.